Biagio Ricciuti
机构：Harvard University, Dana-Farber Cancer Institute
发表论文 9 篇
代表论文
- Impact of STK11 / KEAP1 / SMARCA4 co-mutations in RAS-activated KRAS wild-type metastatic NSCLC treated with immune checkpoint inhibitors. (2026 · Journal of Clinical Oncology)
- Smoking signature as used to define a genomically distinct subset of class I BRAF-mutant NSCLC. (2026 · Journal of Clinical Oncology)
- Molecular and immune profiling of BRAF -mutated ( BRAF MUT ) non-small cell lung cancer (NSCLC). (2026 · Journal of Clinical Oncology)
- Post-progression treatment strategies and immunotherapy rechallenge sensitivity following chemoradiation and consolidation durvalumab in unresectable stage III NSCLC: The POST-PACIFIC study. (2026 · Journal of Clinical Oncology)
- Genomic determinants of resistance to BRAF/MEK inhibitors in BRAF V600E –mutant non–small cell lung cancer. (2026 · Journal of Clinical Oncology)
- Clinical significance of EGFR amplification in patients with EGFR -mutated metastatic non–small cell lung cancer receiving first-line osimertinib. (2026 · Journal of Clinical Oncology)